Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

Core Points - The company announced an adjustment to the management committee of its 2023 employee stock ownership plan [1] - The adjustment was made due to the election of Jiang Shiping as a non-independent director of the company, which required him to resign from the management committee [1] - Wang Xiaohong was elected as a new member of the management committee to protect the overall interests of the employee stock ownership plan [1] Summary by Sections - **Employee Stock Ownership Plan**: The company held a meeting on August 1, 2025, to discuss the management committee of the 2023 employee stock ownership plan, resulting in the election of a new member [1] - **Committee Member Changes**: Jiang Shiping's election to the board necessitated his resignation from the management committee, as per the company's regulations [1] - **New Appointment**: Wang Xiaohong was appointed to the management committee, ensuring she does not hold any significant positions in the company or its controlling entities [1]

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-085 王晓红女士未在公司控股股东或者实际控制人单位担任职务，不属于持有公 司 5%以上股东、实际控制人、董事、监事、高级管理人员，且与前述主体不存 在关联关系。 特此公告。 绿康生化股份有限公司 董 事 会 2025 年 8 月 1 日 绿康生化股份有限公司 关于调整 2023 年员工持股计划管理委员会委员 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）于 2025 年 8 月 1 日以现场结合通讯表决的方式召开 2023 年员工持股计划第二次持有人会议，审 议通过了《关于调整 2023 年员工持股计划管理委员会委员的议案》。 鉴于公司本次员工持股计划管理委员会委员江世平先生当选公司第五届董 事会非独立董事，根据公司《2023 年员工持股计划》第十二章的相关规定："参 加本员工持股计划的公司董事、监事、高级管理人员已承诺不担任管理委员会任 何职务"，因此其辞去管理委员会委员职务。为了更好地保障员工持股计划的整 体利益，本次持有人 ...

Core Viewpoint - The company *ST Lvkang (002868) has received a notification regarding the relocation of its production facilities to improve environmental conditions and comply with local industrial planning [1] Group 1: Company Announcement - The company has been notified by the Fujian Pucheng Industrial Park Management Committee about the relocation of its facilities, including the South Pucheng Ecological Park and Fujian Green An Biological Pesticide Co., Ltd [1] - The relocation is driven by the need to address environmental inspection issues and improve air quality in the urban area as residential zones are increasingly close to the current facilities [1] - The company’s current production operations at the South Pucheng facility and Fujian Green An Biological are still ongoing, and no formal relocation compensation agreement has been signed yet [1] Group 2: Impact on Operations - The specific compensation amount for the relocation is yet to be determined, as it will depend on the formal agreement that has not been finalized [1] - The overall impact of the relocation on the company's operational performance cannot be assessed at this time due to the lack of a signed compensation agreement [1]

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-084 绿康生化股份有限公司 关于公司南浦厂区及控股子公司厂区拟搬迁的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、拟搬迁基本概况 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）于近日收到福建浦城 工业园区管理委员会出具的《关于启动南浦生态园区绿康生化股份有限公司及福建绿安 生物农药有限公司厂区搬迁和用地收储工作的通知》。绿康生化现有两个厂区分别位于 南浦生态园区（简称"南浦厂区"）、浦潭生物产业园区。控股子公司福建绿安生物农 药有限公司（简称"福建绿安生物"）厂区位于南浦生态园区。随着浦城县经济发展、 城区扩容，居民住宅区距离南浦生态园区越来越近，为进一步落实环保督察问题整改、 有效改善城区空气质量、建设美丽城市，同时为加快推进产业集聚，根据浦城县新一轮 的产业规划调整，将绿康生化南浦厂区及福建绿安生物厂区搬迁至浦潭生物产业园区。 截至公告披露日，拟搬迁的绿康生化南浦厂区及福建绿安生物厂区仍在正常生产经 营。 二、对公司的影响 鉴于目前尚未签署正式搬迁补偿协议，具体补偿金 ...

特别提示： 1、绿康生化股份有限公司（以下简称"上市公司"、"公司"或"绿康生 化"）自 2025 年 4 月 30 日起被实施"退市风险警示、其他风险警示"，股票简 称由"绿康生化"变更为"*ST 绿康"，证券代码仍为"002868"。公司股票在 风险警示板交易，股票交易的日涨跌幅限制为 5%。若公司 2025 年度经审计的 财务会计报告相关财务指标再次触及《深圳证券交易所股票上市规则》第 9.3.12 条规定的情形，公司股票将被终止上市。敬请广大投资者理性投资、注意投资风 险。 2、2025 年 4 月 24 日，公司控股股东上海康怡投资有限公司（以下简称"康 怡投资"）、股东杭州义睿投资合伙企业（有限合伙）（以下简称"义睿投资"）、 上饶市长鑫贰号企业管理中心（有限合伙）（以下简称"长鑫贰号"）、杭州皓 赢投资合伙企业（有限合伙）（以下简称"皓赢投资"）与福建纵腾网络有限公 司（以下简称"纵腾网络"）签署了《股份转让协议》，约定由康怡投资、义睿 投资、长鑫贰号、皓赢投资向纵腾网络转让上市公司 46,608,397 股普通股股份， 占上市公司总股本的 29.99%的股份（以下简称"本次股份转让"）。本次股 ...

Core Viewpoint - Green Kang Biochemical is undergoing a significant asset restructuring by transferring its photovoltaic film assets to a related party for a total consideration of 0 yuan, indicating a strategic retreat from the photovoltaic sector due to financial burdens [1][2][3]. Group 1: Asset Transfer Details - Green Kang Biochemical announced the sale of 100% equity in three subsidiaries related to photovoltaic film production to Jiangxi Raoxin New Energy Materials Co., Ltd. for 0 yuan, as this transaction is classified as a related party transaction [1][2]. - The acquiring party, Kangyi Investment, is a controlling shareholder of Green Kang Biochemical, with other involved parties being significant shareholders [2]. Group 2: Financial Performance and Challenges - In 2024, Green Kang Biochemical's photovoltaic film revenue reached 231 million yuan, marking a year-on-year increase of 60.89%, accounting for 35.62% of total revenue [3]. - Despite the revenue growth, the gross margin for photovoltaic films was -38.63%, leading to increased losses for the company [3]. - The company anticipates a net loss of 50 million to 65 million yuan for the first half of 2025, representing a reduction in losses compared to the previous year [3].

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-082 绿康生化股份有限公司 关于重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、绿康生化股份有限公司（以下简称"公司""上市公司"或"绿康生化"） 于 2025 年 6 月 28 日披露的《绿康生化股份有限公司重大资产出售暨关联交 易报告书（草案）》"重大风险提示"及"第十一节风险因素"中，详细披露了 本次交易可能存在的风险因素及尚需履行的其他程序，敬请广大投资者注意投资 风险。 2、截至本公告披露之日，除草案披露的风险因素外，公司尚未发现可能导 致公司董事会或者交易对方撤销、中止本次交易或者对本次交易作出实质性变更 的相关事项，本次交易工作正在有序进行中。公司将根据相关事项的进展情况， 及时履行信息披露义务。 3、本次交易尚需提交公司股东会审议，本次交易能否通过上述审批以及最 终通过审批的时间均存在一定不确定性。公司将根据本次交易的进展情况，严格 按照相关法律法规的规定及时履行信息披露义务，敬请广大投资者及时关注公司 后续公告并注意投资风险。 4、公 ...

Core Viewpoint - The veterinary raw material drug market in China is expected to grow significantly, with a projected market size of approximately 185.1 billion yuan in 2024 and around 200 billion yuan in 2025, driven by increased demand and favorable economic conditions [1][8]. Industry Characteristics and Classification - Veterinary raw material drugs are pharmacologically active substances used directly in the manufacture of veterinary drug formulations, characterized by specificity, regulatory requirements, and high technical barriers [2][4]. - They can be classified by chemical properties into synthetic raw materials, biotechnological raw materials, and natural extracts, and by usage into antimicrobial drugs, antiparasitic drugs, antipyretic analgesics, and diagnostic/treatment aids [4][5]. Current Development Status - The veterinary drug industry in China has rapidly developed, becoming a significant part of the global veterinary drug market, with a projected market size of approximately 600 billion yuan in 2024 and 635 billion yuan in 2025 [6][8]. Market Size and Growth - The veterinary raw material drug market is expected to see a growth from 185.1 billion yuan in 2024 to 200 billion yuan in 2025, reflecting a recovery in demand and controlled supply [8][10]. Market Segmentation - Antimicrobial drugs dominate the veterinary raw material drug market, holding an 84% market share, while antiparasitic drugs account for about 11% [10]. Industry Chain - The industry chain includes upstream components such as basic chemical raw materials and intermediates, midstream production of raw materials through chemical synthesis and fermentation, and downstream processing into veterinary drug formulations for livestock and pet healthcare [12]. Competitive Landscape - The veterinary raw material drug industry in China has a low concentration level, with major companies including Haisheng Pharmaceutical, Qihui Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, among others [14][16]. - The industry is experiencing a shift towards larger, more capable firms as regulatory standards improve, leading to a potential increase in market concentration [14]. Key Enterprises - Guobang Pharmaceutical reported a revenue of 1.831 billion yuan from animal health raw materials in 2024, with a gross margin of 18.86% [16]. - Haisheng Pharmaceutical achieved a revenue of 112 million yuan from raw materials in 2024, with a gross margin of 36.28% [18]. Technology Development Trends - The production of raw materials and intermediates requires significant investment in research and development to improve process technology and compete in higher-margin sectors [20].

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-081 绿康生化股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会召开期间不存在否决或变更提案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 3、本次股东会采取现场投票表决和网络投票表决相结合的方式进行。 一、会议召开和出席情况 1、审议通过了《关于豁免公司实际控制人、董事、高级管理人员自愿性股 1 份限售承诺的议案》 本提案关联股东上海康怡投资有限公司、赖潭平回避表决，回避表决股数为 48,848,260 股，占上市公司总股份的 31.4307%。 总表决情况：同意 26,112,554 股，占出席本次股东会有效表决权股份总数的 99.9426％；反对 2,900 股，占出席本次股东会有效表决权股份总数的 0.0111％； 弃权 12,100 股（其中，因未投票默认弃权 0 股），占出席本次股东会有效表决 权股份总数的 0.0463％。 中小股东总表决情况：同意 2,524,746 股，占出席本次股东会中 ...